Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Andrea Tan maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $49 to $74.
May 29, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs analyst Andrea Tan maintains a Buy rating on Insmed and raises the price target from $49 to $74.
The Buy rating and significant increase in price target from a reputable analyst at Goldman Sachs is likely to positively impact Insmed's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100